PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Aclaris Therapeutics, Inc. (ACRS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US00461U1051

CUSIP

00461U105

Sector

Healthcare

IPO Date

Oct 7, 2015

Highlights

Market Cap

$215.72M

EPS (TTM)

-$0.52

PEG Ratio

-0.13

Total Revenue (TTM)

$27.08M

Gross Profit (TTM)

$14.50M

EBITDA (TTM)

-$61.68M

Year Range

$0.86 - $5.17

Target Price

$8.00

Short %

4.14%

Short Ratio

0.47

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
ACRS vs. BFLY ACRS vs. SGMO
Popular comparisons:
ACRS vs. BFLY ACRS vs. SGMO

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Aclaris Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%200.00%250.00%JulyAugustSeptemberOctoberNovemberDecember
-75.38%
197.16%
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

Aclaris Therapeutics, Inc. had a return of 159.05% year-to-date (YTD) and 169.31% in the last 12 months.


ACRS

YTD

159.05%

1M

-31.31%

6M

136.52%

1Y

169.31%

5Y*

6.68%

10Y*

N/A

^GSPC (Benchmark)

YTD

24.34%

1M

0.23%

6M

8.53%

1Y

24.95%

5Y*

13.01%

10Y*

11.06%

Monthly Returns

The table below presents the monthly returns of ACRS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202410.48%2.59%4.20%-2.42%-14.88%6.80%21.82%-11.94%-2.54%57.39%124.86%159.05%
20237.30%-26.27%-35.07%9.89%-6.07%24.19%-4.82%-24.21%-8.42%-27.30%-82.44%20.04%-93.33%
2022-24.90%36.45%15.70%-28.54%3.81%9.15%10.39%3.24%-1.07%-0.83%-2.50%3.48%8.32%
2021220.71%7.37%13.11%-5.36%-6.75%-21.04%-14.98%8.57%11.04%-3.61%-26.22%13.59%124.73%
2020-34.39%-8.06%-8.77%27.88%6.02%14.89%32.72%14.42%4.47%49.42%-13.02%93.71%242.33%
2019-5.68%-7.03%-7.56%5.18%-25.71%-53.21%-41.55%-21.09%6.93%62.04%-6.29%15.24%-74.42%
2018-10.30%-9.86%-12.14%1.31%1.80%10.51%-14.17%-7.12%-8.79%-18.11%-21.61%-20.71%-70.03%
2017-2.25%17.72%-4.51%-5.73%-15.40%14.05%6.19%-9.97%-0.46%-2.32%-5.95%4.01%-9.14%
2016-17.48%-17.50%3.33%-2.48%8.12%-7.56%6.66%2.34%27.03%-17.02%40.94%-9.38%0.74%
201530.95%62.75%14.39%143.80%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 92, ACRS is among the top 8% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ACRS is 9292
Overall Rank
The Sharpe Ratio Rank of ACRS is 9292
Sharpe Ratio Rank
The Sortino Ratio Rank of ACRS is 9393
Sortino Ratio Rank
The Omega Ratio Rank of ACRS is 9292
Omega Ratio Rank
The Calmar Ratio Rank of ACRS is 9090
Calmar Ratio Rank
The Martin Ratio Rank of ACRS is 9494
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Aclaris Therapeutics, Inc. (ACRS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for ACRS, currently valued at 1.79, compared to the broader market-4.00-2.000.002.001.792.10
The chart of Sortino ratio for ACRS, currently valued at 3.14, compared to the broader market-4.00-2.000.002.004.003.142.80
The chart of Omega ratio for ACRS, currently valued at 1.41, compared to the broader market0.501.001.502.001.411.39
The chart of Calmar ratio for ACRS, currently valued at 1.96, compared to the broader market0.002.004.006.001.963.09
The chart of Martin ratio for ACRS, currently valued at 11.87, compared to the broader market-5.000.005.0010.0015.0020.0025.0011.8713.49
ACRS
^GSPC

The current Aclaris Therapeutics, Inc. Sharpe ratio is 1.79. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Aclaris Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.00JulyAugustSeptemberOctoberNovemberDecember
1.79
2.10
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Aclaris Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-91.76%
-2.62%
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Aclaris Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aclaris Therapeutics, Inc. was 98.05%, occurring on Nov 13, 2023. The portfolio has not yet recovered.

The current Aclaris Therapeutics, Inc. drawdown is 91.76%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.05%Apr 18, 20171656Nov 13, 2023
-49.56%Dec 23, 201563Mar 24, 2016173Nov 29, 2016236
-19.68%Dec 19, 201634Feb 7, 201713Feb 27, 201747
-13.11%Nov 24, 20157Dec 3, 20159Dec 16, 201516
-12.04%Mar 7, 201711Mar 21, 201718Apr 17, 201729

Volatility

Volatility Chart

The current Aclaris Therapeutics, Inc. volatility is 28.28%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%70.00%JulyAugustSeptemberOctoberNovemberDecember
28.28%
3.79%
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Aclaris Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Aclaris Therapeutics, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab